TABLE 2.

Pathologic and postoperative outcomes by receipt of neoadjuvant therapy (NAT) versus upfront resection (UR)

	Extrahepatic cholangiocarcinoma			Ampullary adenocarcinoma			Duodenal adenocarcinoma
	UR (N = 2357)	NAT (N = 157)	p	UR (N = 3668)	NAT (N = 94)	p	UR (N = 1765)	NAT (N = 123)	p
Pathologic stage			0.153			0.639			0.006
I	517 (24.3%)	35 (30.2%)		1265 (37.9%)	30 (40.5%)		279 (17.3%)	5 (5.1%)
II	1610 (75.7%)	81 (69.8%)		2076 (62.1%)	44 (59.5%)		510 (31.7%)	38 (38.4%)
III							820 (51.0%)	56 (56.6%)
T tumor downstaging	–	26 (24.1%)	–	–	19 (28.4%)	–	–	29 (34.1%)	–
N tumor downstaging	–	10 (8.5%)	–	–	10 (15.2%)	–	–	17 (20.2%)	–
Margin positivity (R1/R2)	548 (24.1%)	25 (16.7%)	0.037	116 (3.2%)	2 (2.3%)	1.000	141 (8.2%)	9 (7.7%)	1.000
Tumor grade			0.834			0.364			0.204
G1	276 (12.9%)	13 (14.4%)		455 (13.1%)	13 (17.8%)		151 (9.1%)	8 (7.7%)
G2	1137 (53.0%)	45 (50.0%)		1913 (55.2%)	35 (47.9%)		919 (55.3%)	50 (48.1%)
G3	733 (34.2%)	32 (35.6%)		1096 (31.6%)	25 (34.2%)		591 (35.6%)	46 (44.2%)
Adjuvant chemotherapy	1120 (47.5%)	38 (24.2%)	0.0001	1531 (41.7%)	28 (29.8%)	0.020	731 (41.4%)	31 (25.2%)	<0.001
Length of stay, days	9 (7–14)	9 (7–15)	0.881	10 (7–15)	11 (8–14)	0.916	10 (7–16)	10 (7–15)	0.558
30-Day readmission	191 (8.3%)	11 (7.0%)	0.654	300 (8.3%)	12 (13.0%)	0.125	139 (8.0%)	14 (11.9%)	0.164
30-Day mortality	99 (4.6%)	3 (2.3%)	0.278	116 (3.5%)	1 (1.3%)	0.522	71 (4.4%)	4 (3.8%)	1.000
Follow-up time, months	22 (11–40)	26 (16–47)	0.003	31 (15–55)	31 (17–50)	0.766	28 (12–54)	31 (18–58)	0.114
Median overall survival, months	25.6	38.4	<0.001	52.9	39.6	0.579	48.3	57.8	0.24

Data are presented as n (%), or median (IQR)

UR upfront resection, NAT neoadjuvant therapy, IQR interquartile range, RT radiation therapy